3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Ovarian Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Nivolumab
17
Standard of Care
15
Carboplatin
15
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
130-nm albumin-bound paclitaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
rucaparib
×
90 days
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled